Dry eye syndrome: Neuroptis successfully completes the pre-clinical phase for ML7

Neuroptis is looking to establish industrial and financial partnerships to commence human trials

23-Jan-2015 - Neuroptis announced positive results from a second animal trial of its preservative-free ML7 eye drops. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye syndrome.Both animal trials demonstrated excellent local tolerance and very low systemic absorption. In ...

Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis

27-Sep-2011 - Trophos SA announced that the last patient has now completed the major pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS).Over 500 patients were enrolled in the study and the last patient completed the prescribed study protocol procedures on 15th September. ...

Medicago announces an extension of its agreement with Genopole biopark

29-Nov-2010 - Medicago Inc. announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense. This laboratory is ...

New strategies for cancer drug development urgently needed

Era of personalized oncology required new thinking from governments, companies and clinicians, say experts at ESMO symposium

26-Nov-2010 - Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical ...

ORVACS Phase II clinical study attacks the viral reservoir of HIV patients

10-Nov-2010 - ORVACS (Objectif Recherche VACcin Sida) has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently ...

Trophos initiates pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

19-Oct-2010 - Trophos SA announced the initiation of the pivotal efficacy study of olesoxime in the rare, neurodegenerative condition, Spinal Muscular Atrophy (SMA). The study is substantially funded by Trophos’ partnership with the Association Française contre les Myopathies (AFM). The trial protocol has ...

Neovacs achieves key clinical milestones

23-Jul-2010 - Neovacs announced the achievement of important milestones in its clinical development programs. Consent to proceed to higher dose in the Phase I/II study of IFNalpha Kinoid in lupus patients Recruitment and dosing of the first dose cohort in the Phase 1/2 study of IFNalpha Kinoid in lupus ...

Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant

09-Jul-2010 - Endotis Pharma announced that Phase I clinical trial results for EP217609 were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote, avidin. EP217609 has a ...

EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development

08-Jul-2010 - EyeTechCare SA announced the completion of a EUR 7.5 million funding round. The funds were provided by Lyon-based insurance company SHAM, a first time investor, and Crédit Agricole Private Equity (CAPE), one of EyeTechCare’s existing shareholders. Aelios Finance and MAGS acted as advisers to the ...

Servier and Galapagos initiate strategic alliance in osteoarthritis

02-Jul-2010 - Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new therapies in osteoarthritis (OA). The alliance between Servier and Galapagos builds on novel OA drug targets discovered by Galapagos through its proprietary platform. Galapagos will ...